Biotoxtech Co., Ltd. (KOSDAQ:086040)

Market Cap	54.71B +10.7%
Revenue (ttm)	44.19B +14.9%
Net Income	879.45M
EPS	21.92
Shares Out	15.72M
PE Ratio	158.75
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	260,630
Average Volume	325,133
Open	3,730.00
Previous Close	3,730.00
Day's Range	3,455.00 - 3,730.00
52-Week Range	2,470.00 - 4,115.00
Beta	0.40
RSI	65.84
Earnings Date	Mar 20, 2026

About Biotoxtech

Biotoxtech Co., Ltd. engages in the safety evaluation of synthetic medicines, biomedicines, cell therapy products, gene therapy products, health functional foods, chemicals, and pesticides in South Korea. It is involved in testing and substance screening, clinical pathology and histopathology work, and consulting and government affairs related to non-clinical trials, as well as new drug development. The company’s safety evaluation research field includes general toxicity test, carcinogenicity studies, local toxicity studies, reproductive and de...

• Industry: Medical Laboratories
• Founded: 2000
• Employees: 188
• Stock Exchange: KOSDAQ
• Ticker Symbol: 086040

Financial Performance

In 2024, Biotoxtech's revenue was 41.34 billion, an increase of 26.69% compared to the previous year's 32.63 billion. Losses were -6.43 billion, 31.8% more than in 2023.